Alan Huang, Ph.D.

Alan Huang, Ph.D.

Former Chief Scientific OfficeratTango Therapeutics· In proxies 2022–2023

Pay in FY2023-3% from the year before · Tango Therapeutics stock +36.6% the same year

Alan Huang, Ph.D. was paid $1.8M in FY2023 (Dec), down 3%. Tango Therapeutics stock rose 36.6% that year.

Pay$100 in the stock at the end of FY21 → $90
Pay is from the Summary Compensation Table of each Tango Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Tango TherapeuticsPublic company · 4 yr
    • Former Chief Scientific Officer2022 – Present · 4 yrStock in role +107%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?